Roy Fleischmann

机构：Metroplex Clinical Research Center, Southwestern Medical Center, The University of Texas Southwestern Medical Center · ORCID：0000-0002-6630-1477

发表论文 490 篇 · 总被引 32923 次 · h-index 81

代表论文

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician (2024 · Nature Reviews Rheumatology · 被引 141)
TYK2: an emerging therapeutic target in rheumatic disease (2024 · Nature Reviews Rheumatology · 被引 65)
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2) (2023 · Annals of the Rheumatic Diseases · 被引 39)
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update (2025 · Annals of the Rheumatic Diseases · 被引 37)
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) (2023 · Annals of the Rheumatic Diseases · 被引 36)
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients (2024 · Arthritis & Rheumatology · 被引 35)